Pipeline

Overview

Our pipeline includes clinical-stage drug candidates each with its own unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors.

Voruciclib

Oral CDK9 Inhibitor

Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being evaluated in combination with standard therapy for the treatment of hematologic malignances and solid tumors.

ME-344

Mitochondrial Inhibitor

ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated in combination with stand of care therapy for the treatment of solid tumors.

INVESTIGATIONAL AGENTS	THERAPEUTIC AREA	COMBINATION	PHASE 1/1B	Info
Voruciclib Oral CDK9 Inhibitor Commercial Rights:	Acute Myeloid Leukemia Relapsed/refractory (2L+)	Monotherapy VENCLEXTA^® (venetoclax)	Completed Enrolling	Info
Voruciclib Oral CDK9 Inhibitor Commercial Rights:	Acute Myeloid Leukemia Relapsed/refractory (2L+)	Voruciclib is an orally administered CDK9 inhibitor. Inhibition of CDK9 blocks the production of MCL1, an established resistance mechanism to the BCL2 inhibitor venetoclax. CDK9 also inhibits MYC, a transcription factor regulating cell proliferation and growth that has also been implicated in KRAS mutant tumors. This Phase 1b trial is evaluating voruciclib dose and schedule in patients with acute myeloid leukemia and B-cell malignancies. We are evaluating the dose and schedule of voruciclib as a single-agent and in combination venetoclax, initially in patients with AML and subsequently across multiple indications. Enrollment Status AML: Ongoing B-Cell Malignancies: Ongoing Publications Clinical Trials		Info
ME-344 Mitochondrial Inhibitor Commercial Rights:	HER2-Negative Breast Cancer*	AVASTIN^® (Bevacizumab)	Completed	Info
	HER2-Negative Breast Cancer*	ME-344 is a novel tumor selective mitochondrial inhibitor drug candidate that has been investigated clinically in patients with solid tumors. Data was reported at ASCO 2019 from an investigator-initiated, multi-center, randomized study of ME-344 in combination with placebo or the VEGF inhibitor bevacizumab (marketed as Avastin®). The data demonstrated that ME-344 in combination with bevacizumab was biologically active in HER2 negative breast cancer patients consistent with decreased cancer proliferation. MEI is planning to initiate a Phase 1b clinical study evaluating ME-344 with bevacizumab or other anti-angiogenic agent in patients with select solid tumors. Enrollment Status Study Complete Publications Clinical Trials		Info
	Colorectal Cancer Relapsed	AVASTIN^® (Bevacizumab)	Enrolling	Info
	Colorectal Cancer Relapsed			Info

^*Phase 0 window of opportunity study: investigator initiated, controlled, open label.

Patients & Caregivers

Our driving purpose and principle is simple: deliver novel and differentiated cancer therapies that provide improved outcomes for patients.

Learn More